This article has been updated from a previous version, which incorrectly described the test as predictive instead of prognostic.
NEW YORK (GenomeWeb News) - Genomic Health said today it will work with Pfizer to develop a genomic test to estimate the risk of post-surgery recurrence of a carcinoma.
Genomic Health, working with Pfizer, will use the same technology it uses in its Oncotype Dx breast cancer recurrence test to create the prognostic test for patients with stage I-III renal carcinoma, clear cell type, if the disease has not spread to other parts of the body.
"Many early-stage renal carcinoma patients experience a recurrence of their cancer, yet there is no accurate way to identify the most aggressive cancers in advance,” Genomic Health’s VP of business development, Chu Chang, said in a statement.
"Working together with Pfizer, we have the potential to address a serious unmet need," Chang added.
Financial terms of the agreement were not provided.
News of the agreement gave Genomic Health shares a boost. In mid-afternoon trading, the company’s stock was up 6.16 percent, to $22.75.